Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Sanofi Consumer Healthcare India surged 12.56% to Rs 5385 after the company announced strong financial results for the second quarter of 2025.

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory treatments.